Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


May 22, 2015 10:06 PM ET

Biotechnology

Company Overview of OncoMed Pharmaceuticals, Inc.

Executive Profile

Paul J. Hastings

Chairman, Chief Executive Officer and President, OncoMed Pharmaceuticals, Inc.
AgeTotal Calculated CompensationThis person is connected to 9 Board Members in 9 different organizations across 11 different industries.

See Board Relationships
54$3,211,951
As of Fiscal Year 2014

Background

Mr. Paul J. Hastings has been the Chief Executive Officer and President at OncoMed Pharmaceuticals, Inc. since January 2006 and has been its Chairman since August 2013. Mr. Hastings served as a Business Advisor at Valocor Therapeutics, Inc. He joined OncoMed in 2006. He has over 20 years of experience as a biotechnology and pharmaceutical industry executive. He served as the President and Chief Executive Officer of QLT Inc. from February 2002 to September 2005, where ...

Corporate Headquarters

800 Chesapeake Drive
Redwood City, California 94063

United States

Phone: 650-995-8200
Fax: 650-995-8600

Board Members Memberships

Chief Executive Officer, President, and Director
Director
Director
Director
Chairman
Chairman
Former Director
1998-N/A
Former Chief Executive Officer, President and Director
2000-Present
Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
2002-2005
Former Chief Executive Officer, President and Director
2006-Present
Chairman, Chief Executive Officer and President
2010-Present
Director
2011-Present
Lead Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee
2012-Present
Director, Chairman of Compensation Committee and Member of Nominating & Corporate Governance Committee

Education

BS
University Of Rhode Island

Other Affiliations

Annual Compensation

Salary$469,480
Total Annual Compensation$469,480

Stocks Options

Restricted Stock Awards$698,175
Exercisable Options$515,520
Exercisable Options Value$8,711,560
Unexercisable Options$243,334
Unexercisable Options Value$573,070
Total Value of Options$9,284,629
Total Number of Options$758,854

Total Compensation

Total Annual Cash Compensation$704,220
Total Short Term Compensation$469,480
Other Long Term Compensation$698,175
Total Calculated Compensation$3,211,951
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

COMPETITOR COMPENSATION

There is no Competitor Compensation data available.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact OncoMed Pharmaceuticals, Inc., please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.